It wouldn't be surprising to see some C-met deals coming. I recently started nibbling on both SGXP and ARQL, and figure that even without an imminent deal, they're likely good long term holdings.
>>> ARQL-OP-bet you see a decent trade in the stock in the next few weeks. Howard Liang expects SGXP (not rated) to announce a partnership on their preclinical C-met inhibitor this summer. Hearing there are 10 term sheets out for SGXP drug and shaping up to possibly be the richest preclinical biotech deal ever. ARQL's ARQ-197(c-MET inhib entering ph 2-pancreatic cancer mid:07) is currently partnered only in Jap. Expect the SGXP deal to significantly raise awareness of c-MET class and could be 9 bidders walking away from bidding looking to license a c-MET. T =$12. <<<
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM